Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 211
Filter
Add more filters

Country/Region as subject
Affiliation country
Publication year range
2.
Clin Exp Obstet Gynecol ; 44(2): 299-300, 2017.
Article in English | MEDLINE | ID: mdl-29746045

ABSTRACT

CASE REPORT: A 30-year-old Japanese nulliparous woman visited for pregnancy at 33 weeks with a massive ovarian tumor located in the pouch of Douglas. By preoperative screening, her prothrombin time (PT) and activated partial thromboplastin time (APTT) were prolonged, and her FV activity was significantly decreased to 4.8%. After prophylactic FFP 20 ml/kg was administered and her FV factor was 19.3%, cesarean delivery was performed, and her perioperative course was uneventful. One year later, she underwent a dilatation and evacuation because of a missed abortion, although prophylactic FFP was not administered. During a third pregnancy, after prophylactic FFP 20 ml/kg was administered and FV activity increased to 21.1%, elective cesarean delivery was performed, and her postoperative course was uneventful. CONCLUSION: For surgical therapy or delivery, the goal of therapy is to maintain FV activity above 20%. It is particularly useful to administer prophylactic FFP.


Subject(s)
Cesarean Section/methods , Factor V Deficiency , Obstetric Labor Complications/prevention & control , Plasma , Pregnancy Complications, Hematologic , Factor V Deficiency/diagnosis , Factor V Deficiency/therapy , Female , Humans , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Ovariectomy/methods , Partial Thromboplastin Time/methods , Pregnancy , Pregnancy Complications, Hematologic/diagnosis , Pregnancy Complications, Hematologic/therapy , Pregnancy Complications, Neoplastic/pathology , Pregnancy Outcome , Treatment Outcome
3.
Sci Rep ; 12(1): 1542, 2022 Jan 28.
Article in English | MEDLINE | ID: mdl-35091669

ABSTRACT

We study the critical dynamics of vortices associated with dynamic disordering near the depinning transitions driven by dc force (dc current I) and vortex density (magnetic field B). Independent of the driving parameters, I and B, we observe the critical behavior of the depinning transitions, not only on the moving side, but also on the pinned side of the transition, which is the first convincing verification of the theoretical prediction. Relaxation times, [Formula: see text] and [Formula: see text], to reach either the moving or pinned state, plotted against I and B, respectively, exhibit a power-law divergence at the depinning thresholds. The critical exponents of both transitions are, within errors, identical to each other, which are in agreement with the values expected for an absorbing phase transition in the two-dimensional directed-percolation universality class. With an increase in B under constant I, the depinning transition at low B is replaced by the repinning transition at high B in the peak-effect regime. We find a trend that the critical exponents in the peak-effect regime are slightly smaller than those in the low-B regime and the theoretical one, which is attributed to the slight difference in the depinning mechanism in the peak-effect regime.

5.
J Chem Phys ; 135(3): 034704, 2011 Jul 21.
Article in English | MEDLINE | ID: mdl-21787020

ABSTRACT

The local electronic structures of crystalline and amorphous films of zinc phthalocyanine (ZnPc) and metal-free phthalocyanine (H(2)Pc) have been studied by soft x-ray emission spectroscopy (XES). We found a clear crystalline structure dependence of the elastic-peak shape in the resonant XES spectra. The elastic peaks of both ZnPc and H(2)Pc are found to show an asymmetric shape due to resonant inelastic x-ray scattering (RIXS) at the nitrogen sites for the α-crystalline films, but not for the amorphous films. The observed RIXS feature is ascribed to the charge transfer excitation due to the Raman-active intermolecular interaction, which dominates the excited-electron dynamics in α-crystalline phthalocyanine films.


Subject(s)
Indoles/chemistry , Membranes, Artificial , Organometallic Compounds/chemistry , Crystallization , Isoindoles , Molecular Structure , Spectrometry, X-Ray Emission , Zinc Compounds
6.
Curr Biol ; 31(3): R116-R117, 2021 02 08.
Article in English | MEDLINE | ID: mdl-33561405

ABSTRACT

Surprisingly, the fastest motions are not produced by large animals or robots. Rather, small organisms or structures, including cnidarian stinging cells, fungal shooting spores, and mandible strikes of ants, termites, and spiders, hold the world acceleration records.1-5 These diverse systems share common features: they rapidly convert potential energy - stored in deformed material or fluid - into kinetic energy when a latch is released.4-6 However, the fastest of these are not repeatable, because mechanical components are broken or ejected.5,6 Furthermore, some of these systems must overcome the added challenge of moving in water, where high density and viscosity constrain acceleration at small sizes. Here we report the kinematics of repeatable, ultrafast snaps by tiny marine amphipods (Dulichiella cf. appendiculata). Males use their enlarged major claw, which can exceed 30% of body mass, to snap a 1 mm-long dactyl with a diameter equivalent to a human hair (184 µm). The claw snaps closed extremely rapidly, averaging 93 µs, 17 m s-1, and 2.4 x 105 m s-2. These snaps are among the smallest and fastest of any documented repeatable movement, and are sufficiently fast to operate in the inertial hydrodynamic regime (Reynolds number (Re) >10,000). They generate audible pops and rapid water jets, which occasionally yield cavitation, and may be used for defense. These amphipod snaps push the boundaries of acceleration and size for repeatable movements, particularly in water, and exemplify how new biomechanical insights can arise from unassuming animals. VIDEO ABSTRACT.


Subject(s)
Amphipoda , Movement , Animals , Biomechanical Phenomena , Humans , Male , Water
8.
J Nutr Health Aging ; 23(6): 564-570, 2019.
Article in English | MEDLINE | ID: mdl-31233079

ABSTRACT

OBJECTIVES: To assess the effects of 24 months training on muscle quality, size, strength, and gait abilities in older adults who need long-term care. DESIGN: Non-randomized controlled trial Setting: Kawai Rehabilitation Center and Kajinoki Medical Clinic. PARTICIPANTS: Ten older participants who needed long-term care (age, 76.7 ± 5.6 years) were participated as training group (Tr-group) and 10 older men and women who did not require long-term care (age, 72.9 ± 6.6 years) comprised the control group (Cont-group). INTERVENTION: Tr-group performed resistive and endurance exercises once or twice a week for 24 months. MEASUREMENTS: Using ultrasound images, echo intensity (EI) and muscle thickness were measured in the rectus femoris and biceps femoris as an index of muscle quality and size. Physical performance was measured before and after the training; performance parameters included knee extension peak torque, 5-m normal and maximal walk test, sit-to-stand and timed up and go test. RESULTS: After the training, there was no change in EI, while BF thickness was increased (pre; 1.82 ± 0.29 cm, 24 months; 2.14 ± 0.23 cm, p < 0.05) in Tr-group. Walk-related performances were improved after the training in Tr-group (i.e. 5-m walk test and timed up and go test). The percent change of knee extension peak torque explained the percent change of EI in the rectus femoris (regression coefficient = 1.24, R = 0.91, adjusted R2 = 0.82, p < 0.001). CONCLUSIONS: Twenty-four months' training induced muscle hypertrophy and improved physical functions. Increased muscle quality in the rectus femoris could be a key to improved knee extension peak torque, with the potential to eventually reduce the need for long-term care in older individuals.


Subject(s)
Endurance Training/methods , Muscle Strength/physiology , Muscle, Skeletal/physiology , Resistance Training/methods , Aged , Female , Humans , Long-Term Care , Male , Physical Endurance/physiology , Time Factors
10.
Nutr Diabetes ; 6(11): e233, 2016 11 28.
Article in English | MEDLINE | ID: mdl-27892934

ABSTRACT

Expression of ß-Kotho, fibroblast growth factor receptor (FGFR)-1c and 2c, which bind FGF21, is decreased in the white adipose tissue of obese mice. The aim of the present study was to determine the role of FGFR2c in the development of obesity and diabetes in KKAy mice. Treatment with mouse monoclonal FGFR2-IIIc antibody (0.5 mg kg-1) significantly suppressed body weight gain and epididymal white adipose tissue weight in individually housed KKAy mice while having no effect on daily food intake. In addition, treatment with FGFR2-IIIc antibody significantly increased plasma-free fatty acid levels while having no effect on blood glucose or plasma FGF21 levels. Moreover, treatment with FGFR2-IIIc antibody had no significant effect on the expression of uncoupling protein-1, uncoupling protein-2 or peroxisome proliferator-activated receptor-γ coactivator 1α in the epididymal white adipose tissue. The treatment with FGFR2-IIIc antibody had no significant effects on daily food intake and body weight gain in individually housed KK mice. These findings suggest that FGFR2-IIIc upregulates the adiposity induced by social isolation in KKAy mice, and that decreased expression and/or function of FGFR2c might be a compensatory response to enhanced adiposity. Inhibition of FGFR2-IIIc function might be a novel therapeutic approach for obesity.


Subject(s)
Adipose Tissue/drug effects , Antibodies, Monoclonal/pharmacology , Receptor, Fibroblast Growth Factor, Type 2/immunology , Weight Gain/drug effects , Animals , Antibodies, Monoclonal/administration & dosage , Injections, Intraperitoneal , Male , Mice , Mice, Inbred Strains , Mice, Obese
11.
Biochim Biophys Acta ; 1176(1-2): 20-6, 1993 Mar 10.
Article in English | MEDLINE | ID: mdl-8452875

ABSTRACT

We studied alteration of glycosaminoglycans (GAGs) induced by recombinant human tumor necrosis factor alpha (rhTNF alpha) in vascular smooth-muscle cells from bovine aorta in a culture system. It was found that rhTNF alpha at 10 ng/ml and below significantly increased the incorporation of [35S]sulfate (35S) but conversely decreased that of [3H]glucosamine (3H) into GAGs in the trypsinate fraction of the cell layer after a 24-h incubation. These results suggested that rhTNF alpha reduced the formation and/or the anchorage of sugar chains in the cell layer but enhanced their sulfation in whole GAG synthesis by the cells. In results, the ratio of 35S to 3H in the GAGs was markedly increased. This increase occurred after 24 h and longer when the cells were treated with 1.0 ng/ml rhTNF alpha. The TNF alpha-induced alteration of the incorporation of both 35S and 3H was completely blocked by anti-rhTNF alpha antibody. Other cytokines including recombinant human interleukin-1 beta and -6, and platelet-derived growth factor failed to alter the ratio of 35S to 3H in the GAGs of the trypsinate fraction of the cell layer. In cultured vascular endothelial cells from bovine aorta, however, rhTNF alpha at 1.0 ng/ml significantly decreased the incorporation of both 35S and 3H into GAGs of both the trypsinate fraction and the medium; the ratio of 35S to 3H was not changed. Characterization of GAGs in vascular smooth muscle cell trypsinate fraction revealed that rhTNF alpha at 10 ng/ml induced (i) no change of the incorporation of 3H in the hyaluronate fraction, (ii) a marked increase in the incorporation of 35S and no change of that of 3H in chondroitin sulfates (A plus C) fraction, (iii) a significant decrease in the incorporation of both 35S and 3H in the heparan sulfate fraction, and (iv) no change of the incorporation of 35S and a marked decrease in that of 3H in the dermatan sulfate fraction. In the medium, rhTNF alpha also induced various changes of GAGs. It was therefore concluded that TNF alpha may have a capacity of inducing a qualitative change of vascular smooth-muscle cell GAGs, which may be involved in the vascular pathology such as atherosclerosis.


Subject(s)
Glycosaminoglycans/biosynthesis , Muscle, Smooth, Vascular/drug effects , Tumor Necrosis Factor-alpha/pharmacology , Animals , Aorta , Cattle , Cells, Cultured/drug effects , Glucosamine/metabolism , Glycosaminoglycans/analysis , Interleukin-1/pharmacology , Interleukin-6/pharmacology , Macrophages/metabolism , Muscle, Smooth, Vascular/metabolism , Platelet-Derived Growth Factor/pharmacology , Recombinant Proteins/pharmacology , Sulfates/metabolism , Sulfur Radioisotopes , Tritium , Tumor Necrosis Factor-alpha/metabolism
12.
J Mol Biol ; 227(3): 942-4, 1992 Oct 05.
Article in English | MEDLINE | ID: mdl-1404397

ABSTRACT

Cathepsin B from bovine spleen has been purified and crystallized as a complex with a specific inhibitor CA074 [N-(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L- isoleucyl-L-proline], using the hanging-drop method. The complex crystals obtained from 50 mM-citrate buffer (pH 3.5) belong to the tetragonal space group P4(1) (or P4(3)) with a = 73.06 A and c = 141.59 A, and diffract beyond 2.2 A resolution. There are two complex molecules per asymmetric unit giving a packing density of 3.37 A3/Da and indicating a high solvent content of 63.5%.


Subject(s)
Cathepsin B/chemistry , Dipeptides/chemistry , Animals , Cathepsin B/metabolism , Cattle , Crystallization , Dipeptides/metabolism , Macromolecular Substances , Models, Chemical , X-Ray Diffraction
13.
Br J Radiol ; 78(927): 269-71, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15730996

ABSTRACT

Erythropoietin (EPO)-producing renal cell carcinomas (RCC) in patients with chronic renal failure secondary to autosomal dominant polycystic kidney disease (ADPKD) has not previously been reported. We report a case of EPO-producing RCC associated with ADPKD in a 66-year-old woman, and discuss the clinical and radiological findings.


Subject(s)
Carcinoma, Renal Cell/metabolism , Erythropoietin/metabolism , Kidney Neoplasms/metabolism , Neoplasm Proteins/metabolism , Polycystic Kidney, Autosomal Dominant/complications , Aged , Carcinoma, Renal Cell/complications , Female , Humans , Kidney Failure, Chronic/etiology , Kidney Neoplasms/complications
14.
Arch Intern Med ; 146(5): 995-6, 1986 May.
Article in English | MEDLINE | ID: mdl-3963988

ABSTRACT

A 43-year-old woman with a history of systemic lupus erythematosus manifested severe diarrhea, generalized gastrointestinal polyposis, pigmentation, and onychodystrophy, which were typical of Canada-Cronkhite syndrome. The exacerbation of systemic lupus erythematosus, presenting with hemolytic anemia and subsequently with profound proteinuria, was seen during the course of this syndrome. The patient achieved complete symptomatic remissions of both entities for more than four years following prednisolone therapy; the resolution of the gastrointestinal polyps was confirmed histologically. This case showed that this syndrome could be completely reversible in its course and that it might have an exogenous cause, as previously suggested.


Subject(s)
Lupus Erythematosus, Systemic/complications , Polyps/complications , Stomach Neoplasms/complications , Adult , Female , Humans , Intestinal Polyps/complications , Intestinal Polyps/genetics , Intestinal Polyps/pathology , Nails, Malformed , Polyps/genetics , Polyps/pathology , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Syndrome
15.
Diabetes Metab ; 41(5): 425-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26234524

ABSTRACT

AIM: Glucagon-like peptide-1 (GLP-1), an incretin hormone, is released from intestinal L cells in response to nutrient ingestion. Dipeptidyl peptidase-4 (DPP-4) rapidly degrades the active form of GLP-1 to an inactive form in the bloodstream. The present study aimed to investigate the role of serotonin (5-HT)1B receptors in the regulation of plasma active GLP-1 levels and glucose tolerance under DPP-4 inhibition. METHODS: C57BL6J mice treated with or without alogliptin, a highly selective DPP-4 inhibitor, for 4 days were intraperitoneally injected with either saline, the 5-HT1B/2C receptor agonist meta-chlorophenylpiperazine (mCPP) at 2.5mg/kg and 5mg/kg or the selective 5-HT1B receptor agonist CP94253 at 2.5mg/kg and 5mg/kg, and food-deprived after treatment. An hour later, plasma active GLP-1 levels were determined. Also, a glucose tolerance test was done by injecting D-glucose (2g/kg) following the injection of saline or CP94253 (5mg/kg) in mice treated with alogliptin. RESULTS: Intraperitoneal injection of mCPP (2.5 and 5mg/kg) or CP94253 (2.5 and 5mg/kg) in mice treated with alogliptin for 4 days significantly increased plasma active GLP-1 levels compared with saline controls in mice that were food-deprived after the injections. While intraperitoneal injection of either mCPP or CP94253 alone had no significant effect on plasma active GLP-1 levels, the injection of CP94253 improved glucose tolerance in mice treated with alogliptin compared with saline. CONCLUSION: These findings suggest that pharmacological stimulation of 5-HT1B receptors enhances the increases in plasma active GLP-1 induced by DPP-4 inhibition independently of feeding and also improves glucose tolerance in mice.


Subject(s)
Dipeptidyl Peptidase 4/metabolism , Dipeptidyl-Peptidase IV Inhibitors/therapeutic use , Glucagon-Like Peptide 1/agonists , Glucose Intolerance/drug therapy , Receptor, Serotonin, 5-HT1B/metabolism , Serotonin 5-HT1 Receptor Agonists/therapeutic use , Up-Regulation/drug effects , Administration, Oral , Animals , Dipeptidyl Peptidase 4/genetics , Dipeptidyl-Peptidase IV Inhibitors/administration & dosage , Dose-Response Relationship, Drug , Drug Therapy, Combination , Food-Drug Interactions , Glucagon-Like Peptide 1/blood , Glucose Intolerance/blood , Glucose Intolerance/metabolism , Injections, Intraperitoneal , Insulin/agonists , Insulin/blood , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Male , Mice, Inbred C57BL , Piperazines/administration & dosage , Piperazines/therapeutic use , Piperidines/administration & dosage , Piperidines/therapeutic use , Pyridines/administration & dosage , Pyridines/therapeutic use , Receptor, Serotonin, 5-HT1B/chemistry , Serotonin 5-HT1 Receptor Agonists/administration & dosage , Uracil/administration & dosage , Uracil/analogs & derivatives , Uracil/therapeutic use
16.
J Comp Neurol ; 435(4): 394-405, 2001 Jul 09.
Article in English | MEDLINE | ID: mdl-11406821

ABSTRACT

Lancelets (amphioxus) exhibit a remarkable asymmetric development in the anterior body region, which is reflected in the peripheral nervous system even at adulthood. Not all of the anterior nerves are involved, but the left third to fifth nerves are clearly asymmetric. To trace the developmental process responsible for asymmetric innervation, the peripheral nerves in the anterior region were studied in pre- and mid-metamorphic larvae, 1-cm-long juveniles, and in adults by using whole-mount immunostaining. The mouth changes in size and location during larval life before moving ventrally and, in conjunction with this change, nerves in the oral region are also modified. The left second nerve initially innervates the oral region, but this connection is secondarily lost. As the mouth expands and shifts posteriorly, the left fifth to ninth nerves join the left third and fourth in the innervation of the oral region. The left third to sixth nerves anastomose with the oral nerve ring, which encircles the mouth on the left side. In the juveniles and adults, there are two nerve plexuses that run parallel to the margin of the oral hood. The innermost of these, the "inner oral-hood nerve plexus", is asymmetrically connected with the left third to fifth nerves on both sides. The other, the "outer oral-hood nerve plexus", is ipsilaterally connected with the third to seventh nerves on both sides. The velar nerve ring is also innervated asymmetrically by the left fourth and fifth nerves. From these observations, we suggest that the oral nerve ring is the precursor of both the inner oral-hood nerve plexus and the velar nerve ring, and that the asymmetric innervation retained in adult lancelets is related to the early anastomosis of the left nerves with the oral nerve ring. We also show that, contrary to the persistent asymmetric innervation, the axonal patterns of the anterior peripheral nervous system in developing lancelets can change.


Subject(s)
Chordata, Nonvertebrate/physiology , Functional Laterality/physiology , Peripheral Nervous System/growth & development , Animals , Antibodies, Monoclonal , Coloring Agents , Immunohistochemistry , Invertebrates , Larva/growth & development , Metamorphosis, Biological , Microscopy, Electron, Scanning , Mouth/growth & development , Mouth/innervation , Peripheral Nervous System/anatomy & histology
17.
J Nucl Med ; 37(6): 975-8, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8683325

ABSTRACT

UNLABELLED: We compared the ability of bone SPECT and MRI to detect vertebral metastasis. METHODS: Skeletal scintigraphy, including planar and SPECT imaging, and spinal MRI examinations, were performed in 22 cancer patients in whom a total of 88 metastatic foci and 12 degenerative joint disease lesions were detected. Metastatic foci were defined as lesions that suggested metastasis on MRI and/or bone destruction on radiographs or CT and/or aggravation of increased tracer uptakes on serial bone scans. Image reconstruction of axial, coronal and sagittal sections was processed in a 128 X 128 matrix. MRI studies were performed with a 1.5 tesla signal scanner using fast spin-echo sequences. T1- and T2-weighted images were obtained in the sagittal plane. RESULTS: Twenty patients had at least one vertebral metastasis. MRI diagnosed 86 of the 88 (97.7%) metastatic foci; bone SPECT correctly diagnosed 81 of 88 (92.0%); and planar imaging detected 62 of 88 (70.4%). The two vertebrae with metastasis not detected by MRI were clearly seen by bone SPECT. Extra-vertebral body metastases (e.g. in the pedicle, lamina, transverse and spinous processes) were, however, most often detected by SPECT, followed by MRI and planar imaging (40 versus 32 versus 4). CONCLUSION: Vertebral SPECT, using high-resolution SPECT equipment, produced excellent results that were comparable to and complementary with MRI in detecting vertebral metastasis. Our data suggest that vertebral SPECT is superior to MRI in detecting extra-vertebral body metastasis.


Subject(s)
Magnetic Resonance Imaging , Spinal Neoplasms/secondary , Tomography, Emission-Computed, Single-Photon , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Sensitivity and Specificity , Spinal Neoplasms/diagnosis , Spinal Neoplasms/diagnostic imaging , Spine/diagnostic imaging , Spine/pathology
18.
Aliment Pharmacol Ther ; 15(9): 1485-91, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11552923

ABSTRACT

BACKGROUND: There is controversy about the effect of acid-suppressive therapy on Helicobacter pylori density and the severity of histological gastritis in the corpus. AIM: To evaluate the precise distribution of H. pylori, both on the surface mucus cells and in the surface mucus gel layer, by using Carnoy's fixation and immunostaining for the detection of bacteria. METHODS: A total of 19 peptic ulcer patients with H. pylori infection were studied. All patients received a 6-week course of treatment with omeprazole (20 mg/day). Before and after the therapy, H. pylori density in Carnoy-fixed tissue sections was examined immunohistochemically. The effect of omeprazole therapy on the severity of gastritis was also evaluated. RESULTS: H. pylori density and the grade of gastritis significantly decreased in the antrum after omeprazole therapy. In the corpus, however, there were no significant changes in H. pylori density or the severity of gastritis after omeprazole therapy. CONCLUSION: Carnoy's fixation and immunostaining was found to be useful for the detection of H. pylori in the surface mucus gel layer as well as on the surface mucus cells in biopsy tissue sections. By using this method, H. pylori density decreased in the antrum, but remained unchanged in the corpus after a 6-week course of omeprazole therapy.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Helicobacter pylori/isolation & purification , Omeprazole/therapeutic use , Peptic Ulcer/drug therapy , Peptic Ulcer/pathology , Acetic Acid , Adult , Aged , Aged, 80 and over , Chloroform , Ethanol , Female , Gastric Mucosa/pathology , Humans , Male , Middle Aged
19.
Aliment Pharmacol Ther ; 14(7): 919-22, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10886048

ABSTRACT

BACKGROUND: Sucralfate has an inhibitory action against Helicobacter pylori and enhances the anti-H. pylori activity of antimicrobials. AIM: To evaluate the efficacy and safety of sucralfate-based eradication therapy for H. pylori infection, compared with that based on lansoprazole, in a randomized multicentre study. SUBJECTS AND METHODS: The subjects were 150 H. pylori-positive patients. They were randomly assigned to one of two regimens for 2 weeks: sucralfate 1 g t.d.s., amoxycillin 500 mg t.d.s., and clarithromycin 400 mg b.d. (SAC regimen: 75 patients); or lansoprazole 30 mg o.m. with the same antimicrobial medications (LAC regimen: 75 patients). Cure of infection was assessed by a 13C urea breath test 1 month after completion of treatment. RESULTS: Eight patients (four in the SAC group and four in LAC group) could not continue therapy because of severe diarrhoea, and three did not take the 13C urea breath test after therapy. Cure rates for intention-to-treat, all-patients-treated, and per protocol analysis in the SAC group were 80%, 83%, and 88%, respectively, and those in the LAC group were 87%, 87%, and 92%, respectively. There were no significant differences in cure rate or adverse effects between the two regimens. CONCLUSION: Sucralfate in combination with amoxycillin and clarithromycin is as effective as lansoprazole-based eradication therapy for H. pylori.


Subject(s)
Anti-Ulcer Agents/therapeutic use , Helicobacter Infections/drug therapy , Omeprazole/analogs & derivatives , Sucralfate/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Ulcer Agents/adverse effects , Female , Helicobacter Infections/microbiology , Helicobacter pylori/drug effects , Humans , Lansoprazole , Male , Middle Aged , Omeprazole/therapeutic use , Prospective Studies , Sucralfate/adverse effects , Treatment Outcome
20.
Aliment Pharmacol Ther ; 15(8): 1187-91, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11472321

ABSTRACT

BACKGROUND: The cytoprotective agent, ecabet sodium, inhibits urease activity and growth of Helicobacter pylori. AIM: To evaluate the efficacy and safety of ecabet sodium-based eradication of H. pylori infection, compared with a lansoprazole-based regimen, in a randomized multicentre study. SUBJECTS AND METHODS: A total of 120 H. pylori-positive patients were assigned to one of two treatment regimens for 2 weeks: ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC: 60 patients); or lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC: 60 patients). Cure of infection was assessed by a 13C-urea breath test 1 month after completion of treatment. RESULTS: One patient in the EAC group and two in the LAC group did not complete therapy because of an adverse event, and three did not undergo the 13C-urea breath test. Cure rates for the intention-to-treat, all-patients-treated and per protocol analysis in the EAC group were 85%, 86% and 88%, respectively, whereas those in the LAC group were 85%, 88% and 91%. There were no significant differences in cure rate or adverse events between the two regimens. CONCLUSIONS: Ecabet sodium in combination with amoxicillin and clarithromycin is as effective as lansoprazole-based eradication therapy for H. pylori.


Subject(s)
Abietanes , Anti-Bacterial Agents/therapeutic use , Diterpenes/therapeutic use , Drug Therapy, Combination/therapeutic use , Helicobacter Infections/drug therapy , Helicobacter pylori , Omeprazole/analogs & derivatives , Omeprazole/therapeutic use , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Aged , Amoxicillin/therapeutic use , Breath Tests , Carbon Isotopes , Clarithromycin/therapeutic use , Female , Helicobacter pylori/drug effects , Humans , Lansoprazole , Male , Middle Aged , Penicillins/therapeutic use , Pepsin A/antagonists & inhibitors , Prospective Studies , Treatment Outcome , Urea/analysis , Urea/blood , Urease/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL